ZURICH (Reuters) - Genentech, U.S. biotech unit of Swiss drugmaker Roche holding, said on Monday it had filed a marketing application to U.S. regulators for the use of its experimental drug in combination with another medicine to treat an advanced form of skin cancer. Cobimetinib is designed to be used with another Roche drug called Zelboraf for patients with tumors that have a mutation in a gene known as BRAF that allows melanoma cells to grow. When used in this way, the drug helped people with advanced melanoma live longer without their disease worsening, results of a Phase III trial showed in July.
About
Social Profiles
-
Nurse Kaci Hickox (L) joined by her boyfriend Ted Wilbur speak with the media outside of their home in Fort Kent, Maine Oct...
-
Did you know approximately nine in ten people will catch chickenpox if they haven’t been vaccinated against it? ...
-
Background Metabolic syndrome (MetSyn) increases the incidence of cardiovascular disease. Information on changes in p...
-
Background As the most popular video sharing website in the world, YouTube has the potential to reach and influence a...
-
New Year Health Tips Today, I am going to share few of the very interesting articles on New year healt...
-
Did you know approximately nine in ten people will catch chickenpox if they haven’t been vaccinated against it? ...
-
Background The prevalence of childhood overweight and obesity in developed countries appears to be levelling off. As ...
-
Background Little is known about preschool parents’ cognitions, barriers, supports and modeling of key obesogenic beh...
-
A medical staff holds a package of an experimental candidate vaccine rVSV-ZEBOV against Ebola virus disease at the Universi...
-
Background The dramatic growth of mobile phone (MP) use among young people has increased interest in its possible hea...